Meta‐analysis found high rates of post‐traumatic stress disorder and associated risk factors in parents following paediatric medical events

2021 ◽  
Author(s):  
Aaron Burgess ◽  
Lucy Wilcoxon ◽  
Imogen Rushworth ◽  
Richard Meiser‐Stedman
2021 ◽  
Author(s):  
Nela Klimcik ◽  
Maxime Nguyen ◽  
Philippe D'Athis ◽  
Nathalie Forestier ◽  
Pierre-grégoire Guinot ◽  
...  

Abstract Background: ARSDS requires extensive resuscitation and has major physical sequelae. We evaluated the psychiatric sequelae by conducting a systematic review to determine prevalence of symptoms of depression, anxiety disorders and post-traumatic stress disorder (PTSD) following ARDS, as well as their risk factors.Methods: We conducted a search on Pubmed by including all studies meeting our primary endpoint (prevalence of symptoms of depression, anxiety disorders and PTSD following ARDS) and secondary endpoint (associated risk factors). Results: Included studies found prevalence ranging from 16 to 46% for symptoms of depression, 23 to 62% for symptoms of anxiety disorders and 16 to 47% for symptoms of PTSD. The data were too heterogeneous to conduct a meta-analysis. Among the risk factors associated with a risk factor of depression, anxiety disorders or PTSD after ARDS were; factors related to patient (as an history of mental illness) risk factors related to ICU management (as use opioids and benzodiazepine). Effect of severity of ARDS is not known.Conclusion: This systematic review shows that depression, anxiety disorders and PTSD following ARDS are frequent, long-lasting, disabling and have severe psychiatric consequences. Associated risk factors can be identified and among us use of opioids.


2012 ◽  
Vol 32 (2) ◽  
pp. 122-138 ◽  
Author(s):  
David Trickey ◽  
Andy P. Siddaway ◽  
Richard Meiser-Stedman ◽  
Lucy Serpell ◽  
Andy P. Field

2015 ◽  
Vol 206 (2) ◽  
pp. 93-100 ◽  
Author(s):  
Mathew Hoskins ◽  
Jennifer Pearce ◽  
Andrew Bethell ◽  
Liliya Dankova ◽  
Corrado Barbui ◽  
...  

BackgroundPharmacological treatment is widely used for post-traumatic stress disorder (PTSD) despite questions over its efficacy.AimsTo determine the efficacy of all types of pharmacotherapy, as monotherapy, in reducing symptoms of PTSD, and to assess acceptability.MethodA systematic review and meta-analysis of randomised controlled trials was undertaken; 51 studies were included.ResultsSelective serotonin reuptake inhibitors were found to be statistically superior to placebo in reduction of PTSD symptoms but the effect size was small (standardised mean difference −0.23, 95% CI −0.33 to −0.12). For individual pharmacological agents compared with placebo in two or more trials, we found small statistically significant evidence of efficacy for fluoxetine, paroxetine and venlafaxine.ConclusionsSome drugs have a small positive impact on PTSD symptoms and are acceptable. Fluoxetine, paroxetine and venlafaxine may be considered as potential treatments for the disorder. For most drugs there is inadequate evidence regarding efficacy for PTSD, pointing to the need for more research in this area.


Sign in / Sign up

Export Citation Format

Share Document